Current and future strategies in nonclear-cell metastatic renal cell carcinoma

Area of Science:

• Oncology
• Translational Research
• Genitourinary Cancers

Background:

• Metastatic non-clear-cell renal cell carcinoma (non-ccRCC) presents limited therapeutic options with minimal patient benefit.
• Drug development for rare and heterogeneous non-ccRCC is challenging due to the lack of identified key biological drivers.
• Advances in clinical trials and molecular characterization are generating new expectations for non-ccRCC treatment.

Purpose of the Study:

• To review current therapeutic strategies and clinical trial advancements for metastatic non-clear-cell renal cell carcinoma.
• To highlight the challenges and emerging opportunities in non-ccRCC drug development.
• To discuss the role of molecular characterization in advancing non-ccRCC research.

Main Methods:

• Review of recent randomized and single-arm Phase II clinical trials in non-ccRCC.
• Analysis of molecular characterization initiatives for non-ccRCC subtypes.
• Evaluation of preliminary results from approved agents and investigational combinations.

Main Results:

• The first randomized Phase II study showed no significant benefit of everolimus over sunitinib in first-line non-ccRCC.
• Single-arm trials reported outcomes for sunitinib and everolimus in papillary RCC.
• Molecular characterization revealed significant heterogeneity among non-ccRCC subtypes.

Conclusions:

• Current clinical trial efforts provide preliminary data on approved agents for non-ccRCC.
• Molecular characterization has not yet yielded clinically meaningful results but MET proto-oncogene inhibition shows promise in papillary RCC.
• Optimizing non-ccRCC management requires improved pathological diagnosis, target identification, and dedicated clinical trial designs.